ACTHAR is a FDA approved drug for MS relapses. The purpose of the study is to examine the
efficacy of this agent in improving relapses as measured by advanced MRI and laboratory
1. Advanced serial MRI studies on patients during and after an acute MS relapse. MRI will
be performed at baseline, 1 month after the 1st dose of ACTHAR, and months 3, 6, and 12.
ACTHAR will be administered for 10 days. Patients will start ACTHAR within 48 hours of
2. Serial immune assays on patients during and after an acute MS relapse. Serum and blood
samples with be collected at baseline, last day of ACTHAR (day 10 of therapy), 1 month
post 1st dose, and months 3 and 6.